major gift

Philanthropist gifts historic $50 million to Houston-area university

Mackenzie Scott has gifted tens of millions to Houston-area organizations and institutions, and her latest gift is to Prairie View A&M University. Photo courtesy of Prairie View A&M

Historically Black universities have traditionally been overshadowed and underfunded compared to their non-Black collegiate counterparts. But now, a major public figure's game-changing gift has helped level the playing field for a beloved Houston-area school.

Noted author and philanthropist MacKenzie Scott (many know her as the former wife of Amazon CEO and billionaire Jeff Bezos) has donated a massive $50 million to Prairie View A&M University, the institution announced on December 15. The gift is the largest one-time endowment in the school's 144-year history.

Under terms of the donation, the funds can be used at the discretion of the president to support the needs of the university, per a press release. Administrators have chosen to designate $10 million of the total to create the Panther Success Grant Program, an effort to assist juniors and seniors with unpaid balances created by the financial challenges posed by COVID, the school announced.

"This is a historic gift for Prairie View, coming at a time when the university had already decided and begun to invest heavily in key areas to strengthen its academic programs and improve student success," said Ruth J. Simmons, president of Prairie View, in a statement. "The timing of this gift could therefore not be better."

Simmons adds in a statement that she had been in contact with Scott "about a matter not involving Prairie View," and thus was "stunned and, for a time speechless" when Scott's assistant phoned and revealed the donation.

Another whopping gift from Scott includes $18 million to the Greater Houston YMCA.

In a post on Medium, Scott notes that she and her advisers have disbursed over $4 billion in gifts to 384 organizations across all 50 states, Puerto Rico, and Washington D.C. over the last four months. This is in effort to "accelerate my 2020 giving through immediate support to people suffering the economic effects of the crisis," Scott writes.

Scott's generosity includes myriad Texas organizations and groups, including:

  • Easterseals of Greater Houston
  • Easterseals Rehabilitation Center, San Antonio
  • East Texas Food Bank
  • El Pasoans Fighting Hunger
  • Feeding the Gulf Coast
  • South Texas Food Bank
  • Southeast Texas Food Bank
  • Goodwill Houston
  • Goodwill Industries of Dallas
  • Goodwill Industries of East Texas
  • Goodwill Industries of Fort Worth
  • Goodwill Industries of San Antonio
  • Heart of Texas Goodwill Industries
  • Meals on Wheels Central Texas
  • Meals on Wheels Montgomery County
  • Meals on Wheels North Central Texas
  • Texas A&M International University
  • United Way of El Paso County
  • United Way of San Antonio and Bexar County
  • YMCA of Greater Houston
  • YMCA of Metropolitan Dallas
  • YWCA El Paso del Norte Region
  • YWCA Greater Austin
  • YWCA of Lubbock
  • YWCA San Antonio
------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted